StockData
Zenas BioPharma, Inc. logo

Zenas BioPharma, Inc. (ZBIO) stock

ZBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$27.75−0.18 (-0.64%)

Close on Nov 17, 2026Market cap $1.81BP/E –Yield –

Zenas BioPharma r&d expenses

Research and development expenses are spending on new products and technology.

Zenas BioPharma's R&D Expenses for the twelve months ending Sep 30, 2026 was $237.55M, up 47.1% year over year. For fiscal 2025 it was $168.06M, up 20.8% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$168.06M+20.8%
FY2024Dec 31, 2024$139.14M+131.8%
FY2023Dec 31, 2023$60.03M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$58.47M+70.0%
Q2 FY2026Jun 30, 2026$62.91M+46.2%
Q1 FY2026Mar 31, 2026$60.44M+73.1%
Q4 FY2025Dec 31, 2025$55.72M+13.4%
Q3 FY2025Sep 30, 2025$34.40M+2.6%
Q2 FY2025Jun 30, 2025$43.03M+27.3%
Q1 FY2025Mar 31, 2025$34.92M+54.2%
Q4 FY2024Dec 31, 2024$49.16M+140.8%
Q3 FY2024Sep 30, 2024$33.53M+258.5%
Q2 FY2024Jun 30, 2024$33.81M–
Q1 FY2024Mar 31, 2024$22.65M–
Q4 FY2023Dec 31, 2023$20.42M–
Q3 FY2023Sep 30, 2023$9.35M–

More Zenas BioPharma figures

See a number that looks wrong?